Skip to main content

Deferoxamine Side Effects

Medically reviewed by Drugs.com. Last updated on Aug 26, 2023.

Applies to deferoxamine: injection powder for solution.

Serious side effects of Deferoxamine

Along with its needed effects, deferoxamine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking deferoxamine:

More common

Less common

Incidence not known

Other side effects of Deferoxamine

Some side effects of deferoxamine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

For Healthcare Professionals

Applies to deferoxamine: injectable powder for injection.

General

The most common adverse events were injection site reactions (pain, swelling, infiltration, erythema, pruritus, eschar/crust), and arthralgia/myalgia.[Ref]

Local

Very common (10% or more): Pain, swelling, infiltration, erythema, pruritus, eschar/crust at the injection site

Uncommon (0.1% to 1%): Vesicles, local edema, local burning[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia/myalgia

Common (1% to 10%): Growth retardation, bone disorder (e.g. metaphyseal dysplasia)

Frequency not reported: Muscle spasms, leg cramps, transient bone pain, hyperparathyroid bone disease[Ref]

Gastrointestinal

Common (1% to 10%): Nausea

Uncommon (0.1% to 1%): Vomiting, abdominal pain

Very rare (less than 0.01%): Diarrhea[Ref]

Dermatologic

Common (1% to 10%): Urticaria

Very rare (less than 0.01%): Rash generalized, dermatitis medicamentosa[Ref]

Nervous system

Common (1% to 10%): Headache

Very rare (less than 0.01%): Neurological disturbances, dizziness, precipitation/exacerbation of aluminum-related dialysis encephalopathy (e.g. grand mal seizures, hallucinations, paranoid delusions, dialysis dementia), neuropathy peripheral, paresthesia

Frequency not reported: Convulsion[Ref]

Other

Common (1% to 10%): Pyrexia

Rare (less than 0.1%): Deafness neurosensory, tinnitus

Frequency not reported: Transient depression of serum calcium, reversible aphasia with visual loss and bradycardia[Ref]

Respiratory

Uncommon (0.1% to 1%): Asthma

Very rare (less than 0.01%): Acute respiratory distress, lung infiltration[Ref]

Hematologic

Very rare (less than 0.01%): Blood disorders (e.g. thrombocytopenia, leucopenia, eosinophilia)

Frequency not reported: Inhibition of DNA synthesis in T and B lymphocytes[Ref]

Cardiovascular

Rare (less than 0.1%): Hypotension, tachycardia, shock

Frequency not reported: Cardiac arrhythmias[Ref]

Genitourinary

Frequency not reported: Reddish-brown discoloration of the urine, dysuria[Ref]

Immunologic

Rare (0.01% to 0.1%): Mucormycosis

Very rare (less than 0.01%): Gastroenteritis Yersinia, unusual infections (e.g. Pneumocystis carinii, Yersinia, or Rhizopus)[Ref]

Ocular

Rare (less than 0.1%): Loss of vision, scotoma, retinal degeneration, optic neuritis, cataracts, decreased visual acuity, blurred vision, night blindness, visual field defects, chromatopsia, corneal opacities[Ref]

Hypersensitivity

Very rare (less than 0.01%): Anaphylactic shock, anaphylactoid reaction, angioneurotic edema, allergic skin reactions[Ref]

Renal

Very rare (less than 0.01%): Renal impairment (including a rise in serum creatinine)

Frequency not reported: Acute renal failure, renal tubular disorder, blood creatinine increased, aggravation of pyelonephritis[Ref]

Hepatic

Frequency not reported: Impaired hepatic function, increased transaminases[Ref]

Metabolic

Frequency not reported: Hypocalcemia[Ref]

Endocrine

Frequency not reported: Aggravation of hyperparathyroidism[Ref]

References

1. Product Information. Desferal (deferoxamine). Novartis Pharmaceuticals. 2001.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Cerner Multum, Inc. Australian Product Information.

4. Product Information. Deferoxamine Mesylate (deferoxamine). Hospira Inc. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.